JAN 31, 2023 11:40 AM EST

Translating B-Cell Epitope Peptide-Based Cancer Vaccines to the Clinic Immunotherapies

Speaker

Abstract

Blockade of checkpoint receptors with monoclonal antibodies have shown great clinical success, but some patients develop resistance and remain refractory. Both PD-1/PD-L1 and HER-2 inhibitors have limited efficacy and toxicities. Ongoing clinical studies support the need for combination immuno-oncology agents to save the lives of patients. We introduce a novel PD-L1 B-cell peptide vaccine linked to a “promiscuous” T cell MVF peptide (PDL1-Vaxx) or linked to TT3 via a linker. These vaccines are highly immunogenic and antigenic in animal models. The PD-L1 vaccines elicited high titers of antibodies that inhibit tumor growth, induced PD-1/PD-L1 blockade, decreased proliferation, induced apoptosis and caused ADCC of tumor cells. The combination of PDL1-Vaxx with HER-2 vaccine (B-Vaxx) demonstrated tumor inhibition in D2F2/E2 carcinoma. The anti-PDL1-Vaxx block PD-1/PD-L1 interaction and significantly prolonged anti-tumor responses. The combination of B-Vaxx with either PDL1-Vaxx or PD1-Vaxx demonstrated tumor inhibition. PDL1-Vaxx is a promising safe checkpoint inhibitor vaccine. 


Loading Comments...